poisar

Stocks · News reference

Rapport Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Fiscal.ai

Rapport Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $40.2 million and providing updates on its clinical pipeline, including the RAP-219 program.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading